These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 20478328)

  • 21. Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats.
    Snigdha S; Thumbi C; Reynolds GP; Neill JC
    J Psychopharmacol; 2008 Jul; 22(5):567-71. PubMed ID: 18208914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine and sibutramine have opposing effects on the motivation for palatable food.
    van der Zwaal EM; Janhunen SK; Luijendijk MC; Baclesanu R; Vanderschuren LJ; Adan RA; La Fleur SE
    Behav Pharmacol; 2012 Apr; 23(2):198-204. PubMed ID: 22327018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self-administered nicotine increases fat metabolism and suppresses weight gain in male rats.
    Rupprecht LE; Kreisler AD; Spierling SR; de Guglielmo G; Kallupi M; George O; Donny EC; Zorrilla EP; Sved AF
    Psychopharmacology (Berl); 2018 Apr; 235(4):1131-1140. PubMed ID: 29354872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of thermogenesis in antipsychotic drug-induced weight gain.
    Stefanidis A; Verty AN; Allen AM; Owens NC; Cowley MA; Oldfield BJ
    Obesity (Silver Spring); 2009 Jan; 17(1):16-24. PubMed ID: 19107124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats.
    Terry AV; Warner SE; Vandenhuerk L; Pillai A; Mahadik SP; Zhang G; Bartlett MG
    Neuroscience; 2008 Oct; 156(4):1005-16. PubMed ID: 18801413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats.
    Choi S; DiSilvio B; Unangst J; Fernstrom JD
    Life Sci; 2007 Sep; 81(12):1024-30. PubMed ID: 17822717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects.
    Girault EM; Guigas B; Alkemade A; Foppen E; Ackermans MT; la Fleur SE; Fliers E; Kalsbeek A
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Feb; 387(2):185-95. PubMed ID: 24190543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.
    Cooper GD; Harrold JA; Halford JC; Goudie AJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):428-36. PubMed ID: 17933447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of the adverse effects of olanzapine on lipid metabolism with the antiepileptic zonisamide.
    Stefanidis A; Watt MJ; Cowley MA; Oldfield BJ
    Neuropharmacology; 2017 Sep; 123():55-66. PubMed ID: 28400260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of olanzapine-induced weight gain by the retinoid analog AM-80.
    Richards M; Chiba S; Ninomiya M; Wakabayasi C; Kunugi H
    Pharmacopsychiatry; 2013 Nov; 46(7):267-73. PubMed ID: 24105080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa?
    Hillebrand JJ; van Elburg AA; Kas MJ; van Engeland H; Adan RA
    Biol Psychiatry; 2005 Oct; 58(8):651-7. PubMed ID: 16018979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.
    Liebig M; Gossel M; Pratt J; Black M; Haschke G; Elvert R; Juretschke HP; Neumann-Haefelin C; Kramer W; Herling AW
    Obesity (Silver Spring); 2010 Oct; 18(10):1952-8. PubMed ID: 20168311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs.
    Schmidt RH; Jokinen JD; Massey VL; Falkner KC; Shi X; Yin X; Zhang X; Beier JI; Arteel GE
    J Pharmacol Exp Ther; 2013 Oct; 347(1):126-35. PubMed ID: 23926289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities.
    Cooper GD; Pickavance LC; Wilding JP; Harrold JA; Halford JC; Goudie AJ
    J Psychopharmacol; 2007 Jun; 21(4):405-13. PubMed ID: 17050655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic administration of olanzapine affects Behavioral Satiety Sequence and feeding behavior in female mice.
    Coccurello R; D'Amato FR; Moles A
    Eat Weight Disord; 2008 Sep; 13(3):e55-60. PubMed ID: 19011365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice.
    Yoon S; Noh JS; Choi SY; Baik JH
    Biochem Biophys Res Commun; 2010 Mar; 393(2):235-41. PubMed ID: 20117094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats.
    Cooper GD; Goudie AJ; Halford JC
    J Psychopharmacol; 2010 Jul; 24(7):1069-78. PubMed ID: 19329550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
    Han M; Deng C; Burne TH; Newell KA; Huang XF
    Psychoneuroendocrinology; 2008 Jun; 33(5):569-80. PubMed ID: 18358632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.
    Lykkegaard K; Larsen PJ; Vrang N; Bock C; Bock T; Knudsen LB
    Schizophr Res; 2008 Aug; 103(1-3):94-103. PubMed ID: 18579346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic intracerebroventricular administration of recombinant CART(42-89) peptide inhibits and causes weight loss in lean and obese Zucker (fa/fa) rats.
    Larsen PJ; Vrang N; Petersen PC; Kristensen P
    Obes Res; 2000 Nov; 8(8):590-6. PubMed ID: 11156435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.